Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Health X Platform's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Health X Platform Buyback Yield % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Health X Platform's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Health X Platform Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Health X Platform's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Health X Platform's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Health X Platform (BOM:533259) has a Buyback Yield % of 0.00 as of Aug. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Health X Platform and its competitors. According to the industry distribution chart, Health X Platform ranks #999999 out of 271 companies in the Healthcare Providers & Services industry.
Is Health X Platform's Buyback Yield % too high?
Health X Platform's current Buyback Yield % is 0.00. Based on the distribution chart, Health X Platform ranks #999999 out of 271 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Health X Platform has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Health X Platform's Buyback Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Health X Platform ranks #999999 out of 271 companies for Buyback Yield %. This places Health X Platform in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Health X Platform and its competitors. Health X Platform's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health X Platform stock overvalued right now?
Based on GuruFocus' analysis, Health X Platform (BOM:533259) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹403.22, compared to a current price of ₹307.20 — trading 23.8% below its estimated fair value. The current Buyback Yield % is 0.00. Health X Platform's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Health X Platform (BOM:533259), the current Buyback Yield % is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Health X Platform (BOM:533259) Overvalued in 2026?
Based on GuruFocus' analysis, Health X Platform stock appears to be undervalued.
The current stock price of ₹307.20 is trading 23.8% below its estimated GF Value™ of ₹403.22.
GuruFocus considers Health X Platform to be Modestly Undervalued.
Key valuation signals for BOM:533259:
Buyback Yield %: 0.00
GF Value™: ₹403.22 vs. price of ₹307.20 (23.8% below fair value)
No single metric tells the full story. See the BOM:533259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Health X Platform Ltd, formerly Sastasundar Ventures Ltd is a Core Investment Company. Through its subsidiaries, the company is focused on the business of digital network of healthcare and portfolio management services. Its business segments are; Financial Services, and Healthcare Network. The majority of its revenue is generated from the Healthcare Network segment which includes activities for pathology and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological/radiological investigations. Geographically, the company operates only in India.
69GF Score
Get the complete analysis for BOM:533259
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533259 has been successfully added to your 
